Thiamine and Acute Decompensated Heart Failure: Pilot Study
NCT00680706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131
Last updated 2013-08-21
Summary
Heart failure remains an increasing cause of morbidity and mortality in the United States even in the face of recent advances in the treatment of cardiovascular disease. There is an urgent need to reevaluate the treatment of heart failure. Shifting substrate utilization used in energy metabolism from fatty acids to glucose is beneficial to the heart presumably by increasing the efficiency of ATP production. Several new drugs for the treatment of cardiac ischemia work by this mechanism. There is increasing evidence that patients with heart failure may also benefit by the same type of intervention. Patients with heart failure are known to have low serum thiamine levels because of poor dietary intake and increased urinary excretion. Inadequate thiamine will deleteriously shift substrate utilization from glucose to fatty acids.
We hypothesize that thiamine supplementation will be beneficial for patients with heart failure by increasing glucose and decreasing fatty acid utilization. This will be initially tested in a pilot double-blinded placebo controlled study of thiamine supplementation in diabetic and non-diabetic patients presenting to the emergency department with acute decompensated heart failure.
Conditions
Interventions
- DRUG
-
Thiamine
Thiamine (100 mg) in 50 ml D5W, x 2.
- DRUG
-
D5W (50 ml)
Sponsors & Collaborators
-
Beth Israel Deaconess Medical Center
collaborator OTHER -
Baystate Medical Center
lead OTHER
Principal Investigators
-
Howard Smithline, MD · Baystate Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-01-31
- Primary Completion
- 2010-02-28
- Completion
- 2012-06-30
Countries
- United States
Study Locations
More Related Trials
-
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects
NCT03565328 ·Status: TERMINATED ·Phase: PHASE2
-
Nicotinamide Riboside in Systolic Heart Failure
NCT03423342 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Study of Lipoic Acid on Ischemic Heart Failure
NCT03491969 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Active VItamin D on Left Atrial Volume Index
NCT01630408 ·Status: WITHDRAWN ·Phase: NA
-
Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
NCT04528004 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
NCT05384847 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of CLR325 in Chronic Stable Heart Failure Patients.
NCT02696967 ·Status: COMPLETED ·Phase: PHASE2
-
Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)
NCT01481402 ·Status: COMPLETED ·Phase: NA
-
A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin
NCT06625307 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
NCT00709865 ·Status: COMPLETED ·Phase: PHASE3
-
Micronutrient Supplementation in Patients With Heart Failure
NCT01005303 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806 ·Status: RECRUITING ·Phase: PHASE3
-
The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients
NCT00329485 ·Status: TERMINATED ·Phase: NA
-
SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.
NCT03366181 ·Status: COMPLETED
-
Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure
NCT05816265 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Multiple Dose Study in Heart Failure of BAY 1067197
NCT02040233 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Treatment for Coronary Artery Disease
NCT01228214 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
NCT05532046 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
NCT02814097 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker
NCT01945606 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
NCT05724121 ·Status: RECRUITING
-
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
NCT01982292 ·Status: COMPLETED ·Phase: PHASE2
-
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
NCT00082589 ·Status: COMPLETED ·Phase: PHASE4
-
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
NCT05305911 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
NCT00839007 ·Status: COMPLETED ·Phase: PHASE2